See more : Yapi ve Kredi Bankasi A.S. (YKBNK.IS) Income Statement Analysis – Financial Results
Complete financial analysis of Abeona Therapeutics Inc. (ABEO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Abeona Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Makino Milling Machine Co., Ltd. (6135.T) Income Statement Analysis – Financial Results
- HG Holdings, Inc. (STLY) Income Statement Analysis – Financial Results
- Indorama Ventures Public Company Limited (IVL.BK) Income Statement Analysis – Financial Results
- Suven Life Sciences Limited (SUVEN.NS) Income Statement Analysis – Financial Results
- Amkor Technology, Inc. (AMKR) Income Statement Analysis – Financial Results
Abeona Therapeutics Inc. (ABEO)
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.50M | 1.41M | 3.00M | 10.00M | 0.00 | 3.00M | 837.00K | 889.00K | 1.04M | 925.00K | 2.04M | 4.40M | 1.85M | 481.00K | 352.00K | 291.00K | 57.00K | 0.00 | 0.00 | 549.00K | 1.30M | 1.15M | 243.00K | 107.00K | 15.00K | 100.00K | 435.00K | 167.00K | 2.95M |
| Cost of Revenue | 1.61M | 450.00K | 4.46M | 30.14M | 8.68M | 38.70M | 16.99M | 10.66M | 0.00 | 0.00 | 125.00K | 267.00K | 1.22M | 140.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 239.00K | 277.00K | 107.00K | 0.00 | 0.00 | 0.00 | 0.00 | 580.00K | 8.31M | 0.00 |
| Gross Profit | 1.90M | 964.00K | -1.46M | -20.14M | -8.68M | -35.70M | -16.15M | -9.77M | 1.04M | 925.00K | 1.92M | 4.14M | 632.00K | 341.00K | 352.00K | 291.00K | 57.00K | 0.00 | 0.00 | 310.00K | 1.02M | 1.04M | 243.00K | 107.00K | 15.00K | 100.00K | -145.00K | -8.15M | 2.95M |
| Gross Profit Ratio | 54.14% | 68.18% | -48.80% | -201.39% | 0.00% | -1,190.79% | -1,929.75% | -1,098.54% | 100.00% | 100.00% | 93.88% | 93.94% | 34.20% | 70.89% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 56.47% | 78.61% | 90.67% | 100.00% | 100.00% | 100.00% | 100.00% | -33.33% | -4,878.44% | 100.00% |
| Research & Development | 31.09M | 28.97M | 34.33M | 30.14M | 48.57M | 38.70M | 16.99M | 10.66M | 4.72M | 333.00K | 884.00K | 2.01M | 4.20M | 3.35M | 2.66M | 12.61M | 2.60M | 2.05M | 2.78M | 5.42M | 6.10M | 7.02M | 4.17M | 4.01M | 1.61M | 1.80M | 2.43M | 1.41M | 1.25M |
| General & Administrative | 19.00M | 17.26M | 22.80M | 23.78M | 20.71M | 20.11M | 10.94M | 13.29M | 14.32M | 3.71M | 0.00 | 6.02M | 583.00K | 4.51M | 7.11M | 4.34M | 957.00K | 0.00 | 4.64B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.49M | 0.00 | 0.00 | 0.00 | 3.12M | 0.00 | -4.63B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.00M | 17.26M | 22.80M | 23.78M | 20.71M | 20.11M | 10.94M | 13.29M | 14.32M | 3.71M | 4.83M | 6.02M | 4.08M | 4.51M | 7.11M | 4.34M | 4.08M | 2.81M | 4.64M | 3.20M | 2.51M | 2.28M | 1.96M | 1.74M | 1.47M | 1.50M | 1.78M | 1.94M | 1.35M |
| Other Expenses | 0.00 | 141.00K | 3.25M | 4.59M | 7.82M | 2.36M | 741.00K | 825.00K | 551.00K | 3.72M | 4.84M | 419.00K | 4.31M | 238.00K | 259.00K | 253.00K | 4.36M | 3.12M | 6.84M | 3.97M | 3.14M | 2.72M | 2.38M | 2.16M | 1.76M | 1.70M | 1.95M | 2.06M | 1.35M |
| Operating Expenses | 49.03M | 46.22M | 60.37M | 58.50M | 77.09M | 61.16M | 28.67M | 24.77M | 19.59M | 4.06M | 5.72M | 8.45M | 8.51M | 8.10M | 10.03M | 17.21M | 6.96M | 5.18M | 9.62M | 9.39M | 9.23M | 9.74M | 6.55M | 6.17M | 3.36M | 3.50M | 4.38M | 3.47M | 2.60M |
| Cost & Expenses | 50.64M | 46.67M | 60.37M | 58.50M | 77.09M | 61.16M | 28.67M | 24.77M | 19.59M | 4.06M | 5.85M | 8.72M | 9.72M | 8.24M | 10.03M | 17.21M | 6.96M | 5.18M | 9.62M | 9.63M | 9.51M | 9.85M | 6.55M | 6.17M | 3.36M | 3.50M | 4.96M | 11.78M | 2.60M |
| Interest Income | 2.12M | 431.00K | 69.00K | 1.30M | 1.21M | 1.51M | 525.00K | 2.01M | 4.03M | 45.00K | 251.00K | 242.00K | 1.33M | 2.05M | 29.00K | 178.00K | 125.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 418.00K | 736.00K | 3.67M | 4.12M | 400.00K | 11.00K | 8.00K | 6.00K | 6.00K | 582.00K | 279.00K | 608.00K | 963.00K | 607.00K | 539.00K | 478.00K | 3.51M | 7.44M | 2.10M | 1.39M | 1.28M | 1.28M | 1.17M | 342.00K | 0.00 | 0.00 | 0.00 | 45.00K | 0.00 |
| Depreciation & Amortization | 3.20M | 4.58M | 4.46M | 5.60M | 8.68M | 2.36M | 741.00K | 825.00K | 551.00K | 11.00K | 3.00K | 419.00K | 233.00K | 238.00K | 259.00K | 253.00K | 2.60M | 7.06M | 1.57M | 1.08M | 898.00K | 686.00K | 627.00K | 476.00K | 285.00K | 200.00K | 162.00K | 123.00K | 15.00K |
| EBITDA | -50.57M | -34.38M | -76.80M | -74.52M | -67.61M | -54.31M | -26.58M | -21.05M | -13.97M | -26.19M | 4.73M | -9.51M | -1.32M | -6.69M | -16.54M | -16.48M | -18.12M | 2.99M | -7.56M | -4.93M | -4.53M | -8.01M | -5.68M | -5.58M | -3.06M | -3.30M | -4.36M | -11.49M | 356.00K |
| EBITDA Ratio | -1,444.91% | -3,160.18% | -1,801.70% | -426.17% | 0.00% | -1,811.21% | -3,174.43% | -2,366.93% | -1,343.17% | -332.43% | -173.85% | -82.99% | -341.40% | -1,309.77% | -642.90% | -5,664.60% | 12,847.37% | 0.00% | 0.00% | -1,457.74% | -564.86% | -698.69% | -2,337.86% | -5,216.82% | -20,426.67% | -3,200.00% | -1,030.11% | -6,997.60% | 12.09% |
| Operating Income | -47.14M | -45.26M | -89.84M | -81.42M | -77.09M | -58.17M | -27.84M | -23.88M | -18.55M | -3.13M | -3.80M | -4.32M | -7.88M | -7.76M | -9.68M | -16.92M | -6.90M | -5.18M | -9.62M | -9.08M | -8.21M | -8.70M | -6.31M | -6.06M | -3.35M | -3.40M | -4.52M | -11.61M | 341.00K |
| Operating Income Ratio | -1,346.71% | -3,200.64% | -2,994.53% | -814.20% | 0.00% | -1,940.16% | -3,325.69% | -2,686.28% | -1,783.27% | -338.49% | -186.29% | -98.00% | -426.19% | -1,612.68% | -2,748.86% | -5,812.71% | -12,105.26% | 0.00% | 0.00% | -1,653.73% | -634.21% | -758.50% | -2,595.88% | -5,661.68% | -22,326.67% | -3,400.00% | -1,040.00% | -6,953.89% | 11.58% |
| Total Other Income/Expenses | -7.05M | 11.22M | 4.90M | -2.81M | 808.00K | 1.50M | 517.00K | 2.01M | 4.02M | -23.65M | 8.25M | -6.22M | 5.36M | 220.00K | -7.15M | -300.00K | -15.02M | -8.25M | -4.07M | -1.16M | 1.79M | -684.00K | 281.00K | 630.00K | 41.00K | 0.00 | 83.00K | 151.00K | 0.00 |
| Income Before Tax | -54.19M | -39.70M | -84.94M | -84.23M | -76.28M | -56.67M | -27.32M | -21.87M | -14.53M | -26.78M | 4.45M | -10.53M | -2.52M | -8.98M | -16.83M | -17.22M | -21.92M | 13.42M | -11.62M | -10.24M | -6.94M | -9.38M | -6.03M | -5.43M | -3.31M | 0.00 | -4.44M | -11.46M | 341.00K |
| Income Before Tax Ratio | -1,548.23% | -2,807.36% | -2,831.20% | -842.34% | 0.00% | -1,890.29% | -3,263.92% | -2,460.40% | -1,396.73% | -2,894.92% | 217.87% | -239.15% | -136.09% | -1,866.11% | -4,781.25% | -5,915.81% | -38,450.88% | 0.00% | 0.00% | -1,864.85% | -535.52% | -818.13% | -2,480.25% | -5,072.90% | -22,053.33% | 0.00% | -1,020.92% | -6,863.47% | 11.58% |
| Income Tax Expense | 0.00 | -7.89M | 3.67M | 4.12M | 400.00K | 1.51M | 525.00K | 2.01M | 4.03M | 582.00K | 279.00K | 608.00K | 17.00K | -220.00K | 7.66M | 178.00K | -61.00K | -173.00K | -4.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -83.00K | -151.00K | 0.00 |
| Net Income | -54.19M | -31.81M | -88.61M | -88.35M | -76.68M | -56.67M | -27.32M | -21.87M | -14.53M | -26.78M | 4.45M | -10.53M | -2.53M | -7.54M | -17.34M | -17.22M | -21.86M | -12.87M | -1.70M | -10.24M | -6.94M | -9.38M | -6.03M | -5.43M | -3.31M | -3.40M | -4.44M | -11.46M | 341.00K |
| Net Income Ratio | -1,548.23% | -2,249.58% | -2,953.53% | -883.49% | 0.00% | -1,890.29% | -3,263.92% | -2,460.40% | -1,396.73% | -2,894.92% | 217.87% | -239.15% | -137.01% | -1,566.94% | -4,926.14% | -5,915.81% | -38,343.86% | 0.00% | 0.00% | -1,864.85% | -535.52% | -818.13% | -2,480.25% | -5,072.90% | -22,053.33% | -3,400.00% | -1,020.92% | -6,863.47% | 11.58% |
| EPS | -2.53 | -4.05 | -22.50 | -23.84 | -38.07 | -29.81 | -16.40 | -16.00 | -13.16 | -344.56 | 76.75 | -544.49 | -158.39 | -602.67 | -1.83K | -2.58K | -7.69K | -4.56K | -656.62 | -4.22K | -3.27K | -4.48K | -2.93K | -3.07K | -3.40K | -6.20K | -317.21K | -955.17K | 37.89K |
| EPS Diluted | -2.53 | -4.05 | -22.50 | -23.84 | -38.07 | -29.81 | -16.40 | -16.00 | -13.16 | -344.56 | 76.00 | -544.49 | -158.39 | -602.67 | -1.83K | -2.58K | -7.69K | -4.56K | -656.62 | -4.22K | -3.27K | -4.48K | -2.93K | -3.07K | -3.40K | -6.20K | -317.21K | -955.17K | 37.89K |
| Weighted Avg Shares Out | 21.38M | 7.86M | 3.94M | 3.71M | 2.01M | 1.90M | 1.67M | 1.37M | 1.10M | 77.72K | 20.19K | 19.34K | 15.99K | 12.51K | 9.45K | 6.68K | 2.84K | 2.83K | 2.59K | 2.43K | 2.12K | 2.10K | 2.06K | 1.77K | 974.00 | 548.00 | 14.00 | 12.00 | 9.00 |
| Weighted Avg Shares Out (Dil) | 21.38M | 7.86M | 3.94M | 3.71M | 2.01M | 1.90M | 1.67M | 1.37M | 1.10M | 77.72K | 20.38K | 19.34K | 15.99K | 12.51K | 9.45K | 6.68K | 2.84K | 2.83K | 2.59K | 2.43K | 2.12K | 2.10K | 2.06K | 1.77K | 974.00 | 548.00 | 14.00 | 12.00 | 9.00 |
Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
- On track for PDUFA target action date of May 25, 2024 - CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced, as part of the review process by the U.S. Food and Drug Administration...
Abeona Therapeutics Announces $50 Million Credit Facility
CLEVELAND, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has entered into a $50 million credit facility with the Avenue Venture Opportunities Fund, L.P. The credit agreement, which has a term of three...
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Abeona Therapeutics stock climbs after drug candidate receives FDA Priority Review
Abeona Therapeutics Inc shares jumped 15% to $4.96 in late-morning trading on Monday after the US Food and Drug Administration (FDA) said it would expedite a review of pz-cel (prademagene zamikeracel), the company's proposed treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB), a...
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
- PDUFA target action date is May 25, 2024 - - FDA does not currently plan to hold Advisory Committee meeting for pz-cel BLA - CLEVELAND, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that...
Abeona Therapeutics Inc. (ABEO) Q3 2023 Earnings Call Transcript
Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q3 2023 Results Conference Call November 13, 2023 8:30 AM ET Company Participants Greg Gin - Vice President of Investor Relations & Corporate Communications Vishwas Seshadri - President, CEO and Director Madhav Vasanthavada - Chief...
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
Abeona's first-ever U.S. Biologics License Application (BLA) submission completed in September 2023 FDA decision on priority review and acceptance of BLA for pz-cel (prademagene zamikeracel, formerly known as EB-101) in recessive dystrophic epidermolysis bullosa (RDEB) expected by late-November 2023 Initiated...
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The 7 Most Undervalued Penny Stocks to Buy in October 2023
Investing in undervalued penny stocks is always going to be about the same few things. Most investors are attempting to find cheap, short-term plays with reasonable catalysts in their favor.
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
CLEVELAND, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of EB-101, its investigational autologous, engineered cell...
Source: https://incomestatements.info
Category: Stock Reports